New hope for rare liver cancer: triple therapy trial opens
NCT ID NCT04380545
Summary
This study is testing a combination of three drugs—nivolumab, fluorouracil, and interferon—for people with advanced fibrolamellar carcinoma, a rare liver cancer that cannot be removed by surgery. The main goals are to see if the treatment is safe and if it can shrink tumors or stop the cancer from growing. Researchers will compare results to past treatments to see if this new approach works better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE III HEPATOCELLULAR CARCINOMA AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.